title: Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
authors.affiliation: First Department of Internal Medicine (Medicine and Biosystemic Science), Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Oribe
authors.forename: Tetsuya E
authors.initials: TE
authors.lastname: Tanimoto
authors.forename: Kazuya
authors.initials: K
authors.lastname: Shimoda
authors.forename: Wakako
authors.initials: W
authors.lastname: Hikiji
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsugi
authors.forename: Ken
authors.initials: K
authors.lastname: Takase
authors.forename: Hideho
authors.initials: H
authors.lastname: Henzan
authors.forename: Akihiko
authors.initials: A
authors.lastname: Numata
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
authors.forename: Koji
authors.initials: K
authors.lastname: Nagafuji
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004487:Edema / Q000209:etiology*; D005134:Eye Neoplasms / Q000188:drug therapy*; D005141:Eyelid Diseases / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D017338:Cladribine; D000069283:Rituximab